Abstract
As microsurgical techniques improve, attempts to restore function after severe nerve injury place greater demands upon the use of nerve grafts. Viable Schwann cells within these grafts are necessary to maximize nerve regeneration. Progress in decreasing nerve allograft antigenicity and the host response through immunosuppression may provide results comparable to nerve autografts. Although pretreatment methods aimed at reducing allograft antigenicity have yielded inconsistent and overall unsatisfactory results, cryopreservation can maintain Schwann cell viability and shows promise as a means of tissue banking. In addition, tissue typing for MHC I or II antigens and advances in immunosuppressive therapy have rendered encouraging results in experimental models. The use of transplanted nerve allografts remains experimental, yet efforts to understand the host rejection response, advances in immunotherapy, and the development of neurotrophic factors continue to reveal significant benefits over standard treatment methods.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
